SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector

Virology

Volumn 376, Issue 1, 2008, Pages 165-172

  Kapadia, Sagar U ^a   Simon, Ian D ^a   Rose, John K ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Neutralizing antibodies; SARS; VSV

Indexed keywords

LIVE VACCINE; NEUTRALIZING ANTIBODY; PROTEIN SARS COV S; PROTEIN VSV G; REPLICATION DEFECTIVE SINGLE CYCLE VSV VECTOR; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; VIRUS GLYCOPROTEIN; VIRUS PROTEIN; VIRUS VACCINE; VIRUS VECTOR; VSV DELTA G S;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VERO CELL; VESICULAR STOMATITIS VIRUS; VIRUS RECOMBINANT; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, VIRAL; GENETIC VECTORS; INJECTIONS, INTRAMUSCULAR; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; SARS VIRUS; VESICULAR STOMATITIS INDIANA VIRUS; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES; VIRUS REPLICATION;

MUS; SARS CORONAVIRUS; VESICULAR STOMATITIS VIRUS;

EID: 43749089115     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2008.03.002     Document Type: Article

References (45)

1. Bisht H., Roberts A., Vogel L., Bukreyev A., Collins P.L., Murphy B.R., Subbarao K., and Moss B. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc. Natl. Acad. Sci. U. S. A. 101 17 (2004) 6641-6646
2. Bosch B.J., van der Zee R., de Haan C.A., and Rottier P.J. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J. Virol. 77 16 (2003) 8801-8811
3. Daddario-DiCaprio K.M., Geisbert T.W., Geisbert J.B., Stroher U., Hensley L.E., Grolla A., Fritz E.A., Feldmann F., Feldmann H., and Jones S.M. Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J. Virol. 80 19 (2006) 9659-9666
4. Daddario-DiCaprio K.M., Geisbert T.W., Stroher U., Geisbert J.B., Grolla A., Fritz E.A., Fernando L., Kagan E., Jahrling P.B., Hensley L.E., Jones S.M., and Feldmann H. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet 367 9520 (2006) 1399-1404
5. Drosten C., Gunther S., Preiser W., van der Werf S., Brodt H.R., Becker S., Rabenau H., Panning M., Kolesnikova L., Fouchier R.A., Berger A., Burguiere A.M., Cinatl J., Eickmann M., Escriou N., Grywna K., Kramme S., Manuguerra J.C., Muller S., Rickerts V., Sturmer M., Vieth S., Klenk H.D., Osterhaus A.D., Schmitz H., and Doerr H.W. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348 20 (2003) 1967-1976
6. Egan M.A., Chong S.Y., Rose N.F., Megati S., Lopez K.J., Schadeck E.B., Johnson J.E., Masood A., Piacente P., Druilhet R.E., Barras P.W., Hasselschwert D.L., Reilly P., Mishkin E.M., Montefiori D.C., Lewis M.G., Clarke D.K., Hendry R.M., Marx P.A., Eldridge J.H., Udem S.A., Israel Z.R., and Rose J.K. Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes. AIDS Res. Hum. Retrovir. 20 9 (2004) 989-1004
7. Fukushi S., Mizutani T., Saijo M., Matsuyama S., Miyajima N., Taguchi F., Itamura S., Kurane I., and Morikawa S. Vesicular stomatitis virus pseudotyped with severe acute respiratory syndrome coronavirus spike protein. J. Gen. Virol. 86 Pt 8 (2005) 2269-2274
8. Geisbert T.W., Jones S., Fritz E.A., Shurtleff A.C., Geisbert J.B., Liebscher R., Grolla A., Stroher U., Fernando L., Daddario K.M., Guttieri M.C., Mothe B.R., Larsen T., Hensley L.E., Jahrling P.B., and Feldmann H. Development of a new vaccine for the prevention of Lassa fever. PLoS Med. 2 6 (2005) e183
9. Gillim-Ross L., and Subbarao K. Emerging respiratory viruses: challenges and vaccine strategies. Clin. Microbiol. Rev. 19 4 (2006) 614-636
10. Giroglou T., Cinatl Jr. J., Rabenau H., Drosten C., Schwalbe H., Doerr H.W., and von Laer D. Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein. J. Virol. 78 17 (2004) 9007-9015
11. Guan Y., Zheng B.J., He Y.Q., Liu X.L., Zhuang Z.X., Cheung C.L., Luo S.W., Li P.H., Zhang L.J., Guan Y.J., Butt K.M., Wong K.L., Chan K.W., Lim W., Shortridge K.F., Yuen K.Y., Peiris J.S., and Poon L.L. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 302 5643 (2003) 276-278
12. Iverson L.E., and Rose J.K. Localized attenuation and discontinuous synthesis during vesicular stomatitis virus transcription. Cell 23 2 (1981) 477-484
13. Jones S.M., Feldmann H., Stroher U., Geisbert J.B., Fernando L., Grolla A., Klenk H.D., Sullivan N.J., Volchkov V.E., Fritz E.A., Daddario K.M., Hensley L.E., Jahrling P.B., and Geisbert T.W. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 11 7 (2005) 786-790
14. Kahn J.S., Roberts A., Weibel C., Buonocore L., and Rose J.K. Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge. J. Virol. 75 22 (2001) 11079-11087
15. Kapadia S.U., Rose J.K., Lamirande E., Vogel L., Subbarao K., and Roberts A. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology 340 2 (2005) 174-182
16. Kelley J.M., Emerson S.U., and Wagner R.R. The glycoprotein of vesicular stomatitis virus is the antigen that gives rise to and reacts with neutralizing antibody. J. Virol. 10 6 (1972) 1231-1235
17. Ksiazek T.G., Erdman D., Goldsmith C.S., Zaki S.R., Peret T., Emery S., Tong S., Urbani C., Comer J.A., Lim W., Rollin P.E., Dowell S.F., Ling A.E., Humphrey C.D., Shieh W.J., Guarner J., Paddock C.D., Rota P., Fields B., DeRisi J., Yang J.Y., Cox N., Hughes J.M., LeDuc J.W., Bellini W.J., and Anderson L.J. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348 20 (2003) 1953-1966
18. Lau S.K., Woo P.C., Li K.S., Huang Y., Tsoi H.W., Wong B.H., Wong S.S., Leung S.Y., Chan K.H., and Yuen K.Y. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc. Natl. Acad. Sci. U. S. A. 102 39 (2005) 14040-14045
19. Lawson N.D., Stillman E.A., Whitt M.A., and Rose J.K. Recombinant vesicular stomatitis viruses from DNA. Proc. Natl. Acad. Sci. U. S. A. 92 10 (1995) 4477-4481
20. Lefrancois L., and Lyles D.S. The interaction of antibody with the major surface glycoprotein of vesicular stomatitis virus II. Monoclonal antibodies of nonneutralizing and cross-reactive epitopes of Indiana and New Jersey serotypes. Virology 121 1 (1982) 168-174
21. Li W., Moore M.J., Vasilieva N., Sui J., Wong S.K., Berne M.A., Somasundaran M., Sullivan J.L., Luzuriaga K., Greenough T.C., Choe H., and Farzan M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426 6965 (2003) 450-454
22. Li W., Shi Z., Yu M., Ren W., Smith C., Epstein J.H., Wang H., Crameri G., Hu Z., Zhang H., Zhang J., McEachern J., Field H., Daszak P., Eaton B.T., Zhang S., and Wang L.F. Bats are natural reservoirs of SARS-like coronaviruses. Science 310 5748 (2005) 676-679
23. Marra M.A., Jones S.J., Astell C.R., Holt R.A., Brooks-Wilson A., Butterfield Y.S., Khattra J., Asano J.K., Barber S.A., Chan S.Y., Cloutier A., Coughlin S.M., Freeman D., Girn N., Griffith O.L., Leach S.R., Mayo M., McDonald H., Montgomery S.B., Pandoh P.K., Petrescu A.S., Robertson A.G., Schein J.E., Siddiqui A., Smailus D.E., Stott J.M., Yang G.S., Plummer F., Andonov A., Artsob H., Bastien N., Bernard K., Booth T.F., Bowness D., Czub M., Drebot M., Fernando L., Flick R., Garbutt M., Gray M., Grolla A., Jones S., Feldmann H., Meyers A., Kabani A., Li Y., Normand S., Stroher U., Tipples G.A., Tyler S., Vogrig R., Ward D., Watson B., Brunham R.C., Krajden M., Petric M., Skowronski D.M., Upton C., and Roper R.L. The Genome sequence of the SARS-associated coronavirus. Science 300 5624 (2003) 1399-1404
24. Moore M.J., Dorfman T., Li W., Wong S.K., Li Y., Kuhn J.H., Coderre J., Vasilieva N., Han Z., Greenough T.C., Farzan M., and Choe H. Retroviruses pseudotyped with the severe acute respiratory syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-converting enzyme 2. J. Virol. 78 19 (2004) 10628-10635
25. Natuk R.J., Cooper D., Guo M., Calderon P., Wright K.J., Nasar F., Witko S., Pawlyk D., Lee M., DeStefano J., Tummolo D., Abramovitz A.S., Gangolli S., Kalyan N., Clarke D.K., Hendry R.M., Eldridge J.H., Udem S.A., and Kowalski J. Recombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+Th1 immune responses and are protective in mouse and guinea pig models of vaginal challenge. J. Virol. 80 9 (2006) 4447-4457
26. Niwa H., Yamamura K., and Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108 2 (1991) 193-199
27. Okuma K., Matsuura Y., Tatsuo H., Inagaki Y., Nakamura M., Yamamoto N., and Yanagi Y. Analysis of the molecules involved in human T-cell leukaemia virus type 1 entry by a vesicular stomatitis virus pseudotype bearing its envelope glycoproteins. J. Gen. Virol. 82 Pt 4 (2001) 821-830
28. Palin A., Chattopadhyay A., Park S., Delmas G., Suresh R., Senina S., Perlin D.S., and Rose J.K. An optimized vaccine vector based on recombinant vesicular stomatitis virus gives high-level, long-term protection against Yersinia pestis challenge. Vaccine 25 4 (2007) 741-750
29. Peiris J.S., Guan Y., and Yuen K.Y. Severe acute respiratory syndrome. Nat. Med. 10 12 Suppl (2004) S88-S97
30. Publicover J., Ramsburg E., and Rose J.K. A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector. J. Virol. 79 21 (2005) 13231-13238
31. Ramsburg E., Rose N.F., Marx P.A., Mefford M., Nixon D.F., Moretto W.J., Montefiori D., Earl P., Moss B., and Rose J.K. Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol. J. Virol. 78 8 (2004) 3930-3940
32. Ramsburg E., Publicover J., Buonocore L., Poholek A., Robek M., Palin A., and Rose J.K. A vesicular stomatitis virus recombinant expressing granulocyte-macrophage colony-stimulating factor induces enhanced T-cell responses and is highly attenuated for replication in animals. J. Virol. 79 24 (2005) 15043-15053
33. Reif J.S., Webb P.A., Monath T.P., Emerson J.K., Poland J.D., Kemp G.E., and Cholas G. Epizootic vesicular stomatitis in Colorado, 1982: infection in occupational risk groups. Am. J. Trop. Med. Hyg. 36 1 (1987) 177-182
34. Reuter J.D., Vivas-Gonzalez B.E., Gomez D., Wilson J.H., Brandsma J.L., Greenstone H.L., Rose J.K., and Roberts A. Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease. J. Virol. 76 17 (2002) 8900-8909
35. Roberts A., Kretzschmar E., Perkins A.S., Forman J., Price R., Buonocore L., Kawaoka Y., and Rose J.K. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J. Virol. 72 6 (1998) 4704-4711
36. Roberts A., Buonocore L., Price R., Forman J., and Rose J.K. Attenuated vesicular stomatitis viruses as vaccine vectors. J. Virol. 73 5 (1999) 3723-3732
37. Roberts A., Reuter J.D., Wilson J.H., Baldwin S., and Rose J.K. Complete protection from papillomavirus challenge after a single vaccination with a vesicular stomatitis virus vector expressing high levels of L1 protein. J Virol 78 6 (2004) 3196-3199
38. Rose N.F., Marx P.A., Luckay A., Nixon D.F., Moretto W.J., Donahoe S.M., Montefiori D., Roberts A., Buonocore L., and Rose J.K. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106 5 (2001) 539-549
39. Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R., Icenogle J.P., Penaranda S., Bankamp B., Maher K., Chen M.H., Tong S., Tamin A., Lowe L., Frace M., DeRisi J.L., Chen Q., Wang D., Erdman D.D., Peret T.C., Burns C., Ksiazek T.G., Rollin P.E., Sanchez A., Liffick S., Holloway B., Limor J., McCaustland K., Olsen-Rasmussen M., Fouchier R., Gunther S., Osterhaus A.D., Drosten C., Pallansch M.A., Anderson L.J., and Bellini W.J. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300 5624 (2003) 1394-1399
40. Schlereth B., Rose J.K., Buonocore L., ter Meulen V., and Niewiesk S. Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies. J Virol 74 10 (2000) 4652-4657
41. Schlereth B., Buonocore L., Tietz A., Meulen Vt V., Rose J.K., and Niewiesk S. Successful mucosal immunization of cotton rats in the presence of measles virus-specific antibodies depends on degree of attenuation of vaccine vector and virus dose. J. Gen. Virol. 84 Pt 8 (2003) 2145-2151
42. Schnell M.J., Buonocore L., Whitt M.A., and Rose J.K. The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus. J Virol 70 4 (1996) 2318-2323
43. Schnell M.J., Johnson J.E., Buonocore L., and Rose J.K. Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection. Cell 90 5 (1997) 849-857
44. Simon I.D., Publicover J., and Rose J.K. Replication and propagation of attenuated vesicular stomatitis virus vectors in vivo: vector spread correlates with induction of immune responses and persistence of genomic RNA. J. Virol. 81 4 (2007) 2078-2082
45. Yang Z.Y., Kong W.P., Huang Y., Roberts A., Murphy B.R., Subbarao K., and Nabel G.J. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428 6982 (2004) 561-564